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Background: We herein report the first case of X-linked agammaglobulinemia (XLA) that underwent allogeneic
stem cell transplantation using reduced intensity conditioning (RIC). We chronologically observed the reconstitution
of humoral immunity in this case.
Case presentation: The patient was a 28-year-old Japanese male with XLA who previously had life-threatening
infectious episodes and was referred for the possible indication of allogeneic stem cell transplantation. After a
thorough discussion within specialists from different backgrounds, we decided to perform allogeneic peripheral
stem cell transplantation from his HLA-identical elder brother. Due to the non-malignant nature of XLA, we selected
RIC consisting of fludarabine, cyclophosphamide, anti-thymocyte globulin, and 3 Gy of total body irradiation.
Neutrophil engraftment was achieved on day 11 with complete donor chimerism. No major complications, except
for stage 1 skin graft-versus-host disease, were observed. The patient was discharged on day 75 and has been
followed as an outpatient without any infectious episodes for more than 500 days.
Conclusions: Regarding immune reconstitution, CD19+ cells, IgA, and IgM, which were undetectable before
allogeneic stem cell transplantation (allo-SCT), started to increase in number 10 days after allo-SCT and continued
to increase for more than 1 year. Anti-B antibodies appeared as early as day 10. Total IgG levels decreased after the
discontinuation of IgG replacement and spontaneously recovered after day 350. However, most anti-viral IgG titers,
except EB virus-virus capsid antigen IgG, disappeared after the discontinuation of IgG replacement. A seasonal
vaccination to influenza was performed on day 148, with neither anti-influenza type A nor type B being positive
after the vaccination. The transient transfer of allergic immunity to orchard grass was observed. Similar Bruton’s
tyrosine kinase (BTK) expression levels in monocytes and B-cells were observed between the patient and healthy
control. B-cells in the peripheral blood (PB) of the patient on day 279 showed sufficient proliferation after a CD40L
and IL-21 or CD40L and CpG stimulation. Effective immunoglobulin production and class switching were also
observed after a CD40L and IL-21 or CpG stimulation. Signal joint kappa-deleting recombination excision circles
(sjKRECs) became positive 16 days post-SCT, increased to 6300 copies/μg DNA at 42 days, and were maintained at a
high level thereafter. The recovery of T-cell receptor excision circles (TRECs) was slow, but became detectable 1 year
post-hematopoietic stem cell transplantation (HSCT).
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X-linked agammaglobulinemia (XLA) is a congenital im-
munodeficiency caused by mutations in Bruton’s tyro-
sine kinase (BTK) [1, 2]. Dysfunctions in BTK have been
shown to impair B lymphocyte maturation and immuno-
globulin production, resulting in hypogammaglobuline-
mia. Since cellular immunity is spared, most XLA
patients are treated with the regular replacement of im-
munoglobulin G (IgG) products throughout their life-
time [3]. However, some patients develop significant
infectious complications and their life expectancy is
shortened despite standard therapies [4, 5]. Moreover,
the cumulative cost of IgG replacement is very high [6].
Although allogeneic stem cell transplantation (allo-SCT)
is theoretically a curative option for XLA, the potential
risks accompanying allo-SCT have been a barrier to it be-
coming a standard therapy for XLA. Howard et al. re-
ported the first case series of allo-SCT for XLA. They did
not use a preconditioning regimen based on findings ob-
tained in XLA model mice, in which no stable donor en-
graftment was achieved, resulting in no harm, but no
benefit [6]. Allo-SCT was recently performed on a patient
with XLA coincidentally complicated with acute myeloid
leukemia (AML), in which a myeloablative conditioning
regimen was used because it is the standard treatment for
AML [7]. Since XLA itself is a non-malignant disorder,
reduced intensity conditioning (RIC) may be suitable for
cases of allo-SCT for XLA in order to minimize
transplantation-associated toxicity [8]. We herein present
a successful case of allo-SCT for XLA using RIC, in which
we chronologically observed the clinical course of the re-
constitution of humoral immunity.Methods
Flow cytometry
Intracellular BTK staining was performed as previously
described [9]. Briefly, peripheral blood mononuclear cells
(PBMCs) were labeled with phycoerythrin-conjugated
anti-CD14 (Dako) or CD19 (Beckman Coulter). Cells
were fixed, permeabilized, stained with 2 μg/mL of
anti-BTK (clone 10E10, OriGene Technologies, Inc.) or
isotype monoclonal antibodies (BD Biosciences), and
subsequently stained with 1:2000 dilution of fluorescein
isothiocyanate-conjugated anti-mouse IgG2a (Southern
Biotechnology Associates, Inc.). Stained cells were ana-
lyzed using BD LSRFortessa (BD Biosciences), and data
were processed using FlowJo software (Tree Star Inc.).Proliferation assay
PBMCs were labeled with CFSE (3 μM; eBioscience) at
room temperature for 5 min and stimulated for 4 days
with a CD40 ligand (CD40L, 1 μg/mL; Miltenyi Biotec)
and CpG (1 μg/mL; InvivoGen) or CD40L (1 μg/mL)and IL-21 (50 ng/mL; Miltenyi Biotec). Cells were then
stained for CD19 and analyzed using flow cytometry.
In vitro immunoglobulin production assay
An in vitro immunoglobulin production assay was per-
formed as previously described [10]. Briefly, PBMCs
were stimulated with CpG (1 μg/mL) or the CD40 ligand
(1 μg/mL) and IL-21 (100 ng/mL) and then cultured for
12 days. Immunoglobulin levels in the culture superna-
tants were measured using ELISA. Pooled human serum
with known concentrations of IgG, IgA, and IgM was used
as the standard. The sensitivities of the assays used were
as follows: IgG and IgA, 5 ng/mL, and IgM, 10 ng/mL.
TREC analysis
The levels of T-cell receptor excision circles (TRECs),
signal joint kappa-deleting recombination excision cir-
cles (sjKRECs), and coding joint KRECs (cjKRECs) were
measured by real-time PCR as described previously [11].
RNase P was used as an internal control. Primer and
probe sequences were listed previously [12]. The mini-
mum detectable limit was 10 copies/μg DNA.
Case presentation
The patient was a 28-year-old Japanese male who had
been diagnosed with XLA soon after his birth. He had
been receiving IgG replacement therapy since he was an
infant. Regarding his previous infectious history, he had
chronic sinusitis, which twice required surgery, episodes
of chronic upper respiratory infections, cellulitis pro-
gressing to osteomyelitis, tympanomastoiditis, and men-
ingitis resulting in cerebral hemorrhage. Each episode
was refractory to antibiotic therapy and potentially fatal.
He was referred to our hospital for the possible indica-
tion of allo-SCT. The diagnosis of XLA was confirmed
by the direct sequencing of BTK gene mutations [13].
He had an HLA-identical elder healthy brother. After a
thorough discussion with pediatricians specializing in
hematology, immunodeficiency, and transplantation, we
decided to perform allo-SCT from his elder brother. The
risks associated with allo-SCT were explained to the pa-
tient and his family including the donor. Written informed
consent was obtained from the patient and his family.
HLA of the patient and his elder brother, the donor, was
HLA-A*02:01/24:02 B*40:01/51:01 C (not tested)
DRB1*11:01/14:03, and the blood type of both was A+.
We used a RIC regimen consisting of fludarabine
(FLU) at 30 mg/m2/day for 6 days (days −10 to −5),
cyclophosphamide (CY) at 50 mg/kg/day for 2 days
(days −4 and −3), 3 Gy of total body irradiation (TBI),
and rabbit anti-thymocyte globulin (ATG, Thymoglobulin,
Sanofi) at 1.25 mg/kg/day for 2 days (days −2 and −1). In
order to prevent anaphylaxis by ATG, methylprednisolone
(mPSL) was administered at 2 mg/kg on days −2 and −1.
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sisted of the continuous infusion of cyclosporine (CsA)
starting at a dose of 0.3 mg/kg/day from day −2 and oral
mycophenolate mofetil (MMF) starting at a dose of
30 mg/kg/day from day 2. The target blood concentration
of CsA was set at 500–550 ng/mL up to day 20, 350–
500 ng/mL on days 20–35, and thereafter switched to
oral CsA. Peripheral blood stem cell (PBSC) mobilization
using granulocyte colony-stimulating factor (G-CSF) wasFig. 1 Clinical course associated with the recovery of T and B lymphocytes
a The clinical course was illustrated. Reduced intensity conditioning (RIC) c
body irradiation (TBI). Anti-thymocyte globulin (ATG, Thymoglobulin, Sanofi) w
host disease (GVHD). GVHD prophylaxis consisted of cyclosporine (CsA) and m
(dotted gray) lymphocytes in the peripheral blood (PB) were followed in the ad
were plotted. Whereas IgA (solid gray) and IgM (dotted gray) were not detecte
allo-SCT and peaked on day 20. Anti-B antibodies (the blood type of the r
(solid black) levels decreased after the discontinuation of IgG replacementperformed as described previously [14]. Briefly, leukapher-
esis was performed twice on days 4 and 5 of the G-CSF
administration. PBSCs were freshly transplanted on days 0
and +1. The total dose of PBSCs contained 6.66 × 108 nu-
cleated cells/kg and 4.77 × 106 CD34+ cells/kg. After trans-
plantation, the patient received G-CSF from day 5 to the
day of neutrophil engraftment.
The clinical course of allo-SCT was shown in Fig. 1.
Hematopoietic engraftment was rapidly achieved, with(a) and serum levels of immunoglobulins (b) in the admitted period.
onsisted of fludarabine (FLU), cyclophosphamide (CY), and 3 Gy of total
as added for the purpose of prophylaxis for rejection and graft-versus-
ycophenolate mofetil (MMF). The numbers of CD3+ (solid gray) and CD19+
mitted period. b Serum immunoglobulin levels in the admitted period
d before allo-SCT, the titers of both rapidly increased within 1 week of
ecipient and donor was A+) were also detected as early as day 10. IgG
therapy and were maintained at more than 500 mg/dL
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and platelet count of >50 × 109/L on day 25. The donor
chimeras of CD3+ and neutrophil fractions in PB were
100 and 68.2 %, respectively, on day 3 using an inform-
ative short tandem repeat (STR)-PCR technique, and
100 % donor chimerism was confirmed in the CD3+ and
neutrophil fractions on day 10. Since there was no evi-
dence of GVHD, MMF was discontinued on day 23.
Stage 1 skin GVHD developed on day 44, which disap-
peared after slightly increasing the dose of CsA. Weekly
IgG replacement was discontinued on day 43. He was
discharged on day 75 and has been doing well without
any infectious episodes until the last day of the follow-
up on day 500.Fig. 2 Recovery of lymphocyte fractions (CD3+ (solid black), CD4+ (solid thic
black)) (a) and serum levels of immunoglobulins (b) in the long-term follow
more than 500 mg/dL without supplementation and has gradually increase
to normal ranges, with a marked increase being observed in IgMChronological observations of immune recovery
Lymphocyte recoveries during the admitted and long-
term follow-up periods were shown in Figs. 1a and 2a,
respectively. CD19+ cells, which were undetectable be-
fore allo-SCT, started to increase in number 10 days
after allo-SCT and continued to increase for more than
1 year. On the other hand, CD3+ cells decreased by an
order of 101/μL and recovered by an order of 102/μL.
Regarding comparisons of CD3+ and CD56+ cells,
CD56+ cells were dominant until day 250, with the
number of CD3+ cells thereafter increasing to more than
that of CD56+ cells. Regarding comparisons of CD4+ and
CD8+ cells, CD8+ cells were always more dominant than
CD4+ cells.k gray), CD8+ (solid thin gray), CD19+ (dotted gray), and CD56+ (dotted
-up period. The total level of IgG (solid black) has been maintained at
d. IgA (dotted gray) and IgM (solid gray) have been gradually increasing
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est in this case. IgA and IgM, which were undetectable
before allo-SCT, rapidly increased by day 20 (Fig. 1b).
Since the blood type of the patient and donor was A+,
we followed the titer of anti-B antibodies and found that
it appeared as early as on day 10. IgG levels decreased
after the discontinuation of IgG replacement and grad-
ually recovered from day 350 (Fig. 2b). Regarding anti-
bodies to several viruses, all anti-viral IgG, except for EB
virus-virus capsid antigen IgG (EBV-VCA IgG), disap-
peared after the discontinuation of IgG replacement
(Table 1). All anti-viral IgM remained negative before
and after allo-SCT. A seasonal vaccination to influenza
was performed on day 148, with neither anti-influenza
type A nor type B being positive after the vaccination.
We then examined data related to allergies. The radio-
immunosorbent test (RIST), which reflects the total
amount of IgE, was undetectable on days 2 and 46 but
became positive on day 393 after allo-SCT. Among the
various allergens tested, only the radioallergosorbent test
(RAST) to orchard grass, to which the donor had a high
titer of RAST, slightly increased after allo-SCT (day 46)
(Table 2). The donor has seasonal hay fever to orchard
grass, whereas the patient has no symptoms of hay fever.
We also performed functional tests. BTK protein ex-
pression levels and B-cell functional responses were
evaluated on day 279 (Fig. 3a). Similar BTK expression
levels in monocytes and B-cells were observed between
the patient and healthy control as expected. In order to
investigate B-cell functional responses, an in vitroTable 1 Virus-specific IgM and IgG antibodies
The titers of virus-specific antibodies were monitored before and after allo-SCT. IgG
EBV-VCA IgG
NT not testedproliferation assay (Fig. 3b) and immunoglobulin pro-
duction assay (Fig. 3c) were performed. B-cells from the
patient showed sufficient proliferation after a CD40L
and IL-21 or CD40L and CpG stimulation. Effective im-
munoglobulin production and class switching were also
observed after a CD40L and IL-21 or CpG stimulation.
In order to assess T-cell and B-cell neogenesis, we moni-
tored data for TRECs, cjKRECs, and sjKRECs (Fig. 4).
sjKRECs, which serve as an indicator of B-cell neogen-
esis, became positive 16 days post-SCT, increased to
6300 copies/μg DNA at 42 days, and were maintained at
a high level thereafter. B-cell recovery was superior to
the previously reported time course of sjKRECs post-
hematopoietic stem cell transplantation (HSCT) [12].
The recovery of TRECs was slow, but became detectable
1 year post-HSCT. The patient achieved immune recon-
stitution with a normal immune cell configuration judg-
ing from a flow cytometric analysis of PBMCs (data not
shown).
Discussion
XLA is a congenital humoral immunodeficiency caused
by BTK gene mutations. A standard treatment for XLA
is regular IgG replacement, through which a long life ex-
pectancy may be achieved [3]. However, some patients de-
velop chronic infectious episodes despite IgG replacement
and have a shorter life expectancy [4, 5]. Theoretically,
allo-SCT is a curative option for XLA; however, the risk of
treatment-related mortality has been a barrier to allo-SCT
being performed for XLA. The first case series of allo-SCTtiters disappeared after the discontinuation of IgG replacement, except for
Table 2 Allergic responses
Standard Donor Day −12 Day 46 Day 393
IgE-RIST (0–173) 340 <5 <5 23.9
Orchard grass (0–0.34) 67.7 <0.1 <0.26 <0.10
Cedar (0–0.34) 24.4 <0.1 <0.1 <0.1
Cypress (0–0.34) 3.34 <0.1 <0.1 <0.1
Dermatophagoides pteronyssinus (0–0.34) 0.2 <0.1 <0.1 <0.1
Dermatophagoides farinae (0–0.34) 0.19 <0.1 <0.1 <0.1
Cat’s dandruff (0–0.34) <0.1 <0.1 <0.1 <0.1
House dust 1 (0–0.34) 0.16 <0.1 <0.1 <0.1
House dust 2 (0–0.34) 0.20 <0.1 <0.1 <0.1
The radioimmunosorbent test (RIST) indicating the total amount of IgE and radioallergosorbent test (RAST) indicating allergen-specific IgE was monitored before
and after allo-SCT. RIST was undetectable until day 46 and became positive on day 393. The titer of RAST specific to orchard grass, to which the donor had a high
titer of RAST, slightly increased on day 46
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XLA patients received transplants from their HLA-
matched siblings without a preconditioning regimen,
based on findings obtained in XLA model mice, X-
linked immunodeficiency (xid) [6]. In contrast to xid,
stable donor engraftment was not achieved in human
cases, and resulted in no harm, but to no benefit.Fig. 3 Intracellular BTK expression and B-cell functional responses. A blood
a Flow cytometric analysis of BTK expression in monocytes and B-cells. Gray h
expression. b CFSE-labeled proliferation induced by CD40L and CpG or CD40
of divided cells. c Immunoglobulin production induced by CD40L and IL-21 oAbu-Arja et al. recently reported successful allo-SCT
in a patient with XLA and AML, in which they used a
myeloablative conditioning regimen because it is the
standard treatment for AML [7]. They suggested the
use of a RIC regimen in the case of allo-SCT for XLA.
In the present study, we described a case of allo-SCT
for XLA using RIC (Table 3).sample collected from the patient on day 279 was used for these assays.
istograms indicate isotype control and black histograms indicate BTK
L and IL-21 in CD19+ B-cells. Numbers in the plots indicate the percentage
r CpG
Fig. 4 TRECs and KRECs as markers of T- and B-cell neogenesis.
sjKRECs (dotted black), which serve as an indicator of B-cell neogenesis,
became positive 16 days post-SCT, increased to 6300 copies/μg DNA
at 42 days, and were maintained at a high level thereafter. cjKRECs
(solid black), an indicator of B-cell numbers, fluctuated almost in parallel
with sjKRECs. The recovery of TRECs (solid gray) was slow, but became
detectable 1 year post-HSCT
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conditioning is critical. Baron et al. previously reported
the findings of a phase II multicenter randomized study
comparing non-myeloablative allo-SCT with either FLU
plus 2 Gy of TBI (FLU-TBI) or 8 Gy of total lymphoid
irradiation plus ATG (TLI-ATG) [15]. The TLI-ATG
regimen reduced the 2-year cumulative incidence of
moderate/severe chronic GVHD to 17.8 % and increased
the 4-year cumulative incidence of relapse/progression
to 50 %. These findings indicate that the suppression of
chronic GVHD by ATG ameliorates graft-versus-
leukemia (GVL) effects and further relapses, thereby off-
setting the benefit of low GVHD by a high relapse rate
and resulting in the same overall survival rate in malig-
nant diseases. Since XLA is a benign disease and has no
GVL effects, the use of ATG may be beneficial to allo-
SCT for XLA. As an example of a regimen for adultTable 3 Reports of allogeneic stem cell transplantation (allo-SCT) fo
Case number Preconditioning GVHD prophylaxis
Howard et al. N = 1 (−) (−)
N = 3 (−) CsA/MMF
Abu-Arja et al. N = 1 ETP/CY/12Gy TAC/MTX
Ikegame et al. N = 1 FLU/CY/ATG/3Gy CsA/MMF
There are two English reports of allo-SCT for XLA. Howard et al. present six cases based
GVHD prophylaxis, while the other three underwent GVHD prophylaxis consisting of c
engraftment or increases in CD19+ cell numbers or immunoglobulin (Ig) levels [6]. Abu
they used a myeloablative conditioning regimen consisting of etoposide 40 mg/kg for
(ETP/CY/12Gy), and GVHD prophylaxis consisting of tacrolimus and methotrexate (TAC
CD19+ cell numbers and Ig levels. In our case, the preconditioning regimen used comp
ATG/3Gy), and GVHD prophylaxis was CsA and MMF (CsA/MMF). As described in the te
in CD19+ cell numbers and the production of Ig. To the best of our knowledge, this isnon-malignancies, Bacigalupo et al. employed FLU/CY/
ATG with or without low-dose TBI to treat acquired se-
vere aplastic anemia [16]. They demonstrated that the
rejection rate was high in older patients without TBI,
and some centers in Europe have introduced low-dose
TBI. Although the regimen of busulfan, FLU, and ATG
may be another option, a high graft failure rate (21 %)
was reported for children with non-malignant disorders
and chronic myelogenous leukemia [17]. Arai et al. pre-
viously demonstrated the significance of high-dose cytar-
abine added to CY/TBI for bone marrow transplantation
(BMT) and peripheral blood stem cell transplantation
(PBSCT) for myeloid malignancy [18]. In contrast to the
findings obtained for cord blood stem cell transplant-
ation, no additional benefit was observed in BMT or
PBSCT, which did not justify the addition of cytarabine
to the regimen in this case. Regarding GVHD prophy-
laxis, although the combination of CsA plus methotrex-
ate (CsA/MTX) is the current standard for SCT from
HLA-identical sibling donors, MMF in combination with
a calcineurin inhibitor, tacrolimus, or CsA has recently
been highlighted for its potential in achieving rapid
hematopoietic recovery and mild mucosal toxicity [19].
A head-to-head comparison of MMF in combination
with CsA (CsA/MMF) and CsA/MTX was performed by
Piñana et al., in which they showed that CsA/MMF sup-
pressed acute and chronic GVHD to the same extent as
CsA/MTX and also reduced the incidence of mucositis
more than CsA/MTX after RIC PBSCT [20]. Lai et al.
more recently reported the beneficial outcomes of a
combination of CsA, MTX, and MMF (CsA/MTX/
MMF) [21]. It has not yet been established whether pro-
longed neutrophilia and strong immunosuppression by
CsA/MTX/MMF counterbalances SCT for benign im-
munodeficiency disorders. Based on these findings, we
prefer to use a RIC regimen consisting of FLU, CY,
ATG, and 3 Gy of TBI followed by prophylaxis for
GVHD consisting of CsA and MMF for adult patients
with non-malignant disorders, such as aplastic anemia
or paroxysmal nocturnal hemoglobulinemia, which mayr XLA




Yes Yes This report
on their experience, three of which underwent SCT without preconditioning or
yclosporine and mycophenolate mofetil (CsA/MMF). No patients achieved donor
-Arja et al. reported successful allo-SCT in a patient with XLA and AML, in which
1 day, cyclophosphamide (CY) 60 mg/kg/day, and 12 Gy of total body irradiation
/MTX). The patient achieved engraftment with donor chimerism and had normal
rised fludarabine, CY, rabbit anti-thymocyte globulin, and 3 Gy of TBI (FLU/CY/
xt, the patient achieved engraftment with donor chimerism, with a rapid increase
the first English case report of successful allo-SCT for XLA
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related toxicity [22]. We applied this regimen to our
XLA case in order to minimize toxicity and achieve the
permanent reconstitution of the immune system.
In spite of the advances in SCT techniques described
above, the indication of allo-SCT for immunodeficiency
disorders needs to be carefully considered in each case.
Wehr et al. summarized multicenter experiences in allo-
SCT for common variable immunodeficiency (CVID)
[23]. The reasons for selecting allo-SCT included lymph-
oma (24 %), severe infections (12 %), and complex
immunological dysfunctions such as cytopenia and in-
flammatory organ involvement (60 %). Although allo-
SCT in patients with CVID was beneficial in most sur-
viving patients, high mortality was associated with
GVHD and infectious complications. The indication of
allo-SCT for XLA is also difficult to define due to con-
flicting findings on the mortality rate of XLA patients
[4]. Although most XLA patients may experience a
nearly normal life [5], Abolhassani et al. reported that
26.8 % of patients died during a follow-up period of
20 years [24]; the hospitalization rate for patients was
significantly higher than alive patients. The cause of
death among the 11 patients was mainly end-stage of
chronic lung disease in addition to one case of meningi-
tis. According to a national survey conducted in Japan,
the 5-year survival rate of allo-SCT for aplastic anemia
from related donors was more than 80 %. Due to ad-
vances in the SCT technique, repetitive episodes of
hospitalization and/or central nervous system lesions
may facilitate allo-SCT as a treatment option for XLA.
Before discussing immune reconstitution in this case,
the possible impact of ATG needs to be considered from
qualitative and quantitative aspects. Two kinds of rabbit
ATGs are commonly used in SCT conditioning: anti-
Jurkat T-cell line globulin (thymoglobulin) and anti-
thymocyte globulin Fresenius (ATG-F). ATG-F was pre-
viously reported to affect the reconstitution of not only
T-cells but also B-cells [25]. Since we used thymoglobu-
lin in this case, its impact on B-cells was considered to
be minimal. Admiraal et al. found a relationship between
the dose of ATG and immune reconstitution in pediatric
SCT. The commonly used dose regimen of thymoglobu-
lin in SCT is 10 mg/kg worldwide. They found that the
area under the curve of ATG increased, the achievement
of successful immune recognition (defined as CD4+ T-
cells >0.05 × 109 cells per liter in two consecutive mea-
surements within 100 days) decreased, and successful im-
mune reconstitution by day 100 was associated with an
increase in overall survival caused by reduced non-relapse
mortality and relapse-related mortality [26]. Fu et al.
showed that the incidence of late-onset hemorrhagic
cystitis after haploidentical SCT was higher in high-
dose ATG (thymoglobulin 10 mg/kg) than in low-doseATG (thymoglobulin 6 mg/kg) [27]. Since we previously
demonstrated that even a low dose of ATG, thymoglo-
bulin 2.5 mg/kg, was sufficient to control GVHD at an
acceptable level in the Japanese population based on
our experience of more than 500 cases of haploidentical
SCT [28], we used thymoglobulin 2.5 mg/kg in this case
and considered the effects of ATG on T-cell recovery to
have also been minimized.
In our case, CD19+ cells in PB rapidly increased in
number after allo-SCT, and this was accompanied by
IgA and IgM production. Moreover, anti-B antibody pro-
duction, as an example of specific antibody production,
was observed as early as on day 10. Although the total
amount of IgG in PB spontaneously recovered, the titer
of virus-specific antibodies, except for EBV-VCA IgG,
disappeared after the discontinuation of IgG replace-
ment. A vaccination for influenza virus was unsuccessful
in the first season after allo-SCT. Thus, pathogen-
specific immune responses had not fully recovered 1 year
after allo-SCT. This may be explained by T-cell reconsti-
tution not being thoroughly achieved, as shown by the
TREC analysis (Fig. 4). Nevertheless, the patient has
been doing well without any infectious episodes, which
had previously occurred and were life-threatening. An-
other interesting result was the possible transfer of im-
mune or allergic responses from the donor. In this
setting, the donor had a high titer of RIST and RAST to
some allergens. The recipient exhibited a slight increase
in RAST to orchard grass on day 46, implicating the
transient transfer of allergic immunity.Conclusions
Although we had to carefully observe the clinical course
because of the short follow-up period, allo-SCT with
RIC induced rapid and stable engraftment without any
severe complications. IgA and IgM started to increase
within a few weeks. Total IgG levels gradually increased,
whereas virus-specific antibodies disappeared after the
discontinuation of IgG replacement. The patient was free
from life-threatening infectious episodes after allo-SCT.Abbreviations
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Ig: immunoglobulin; IgG: immunoglobulin G; MMF: mycophenolate mofetil;
mPSL: methylprednisolone; MTX: methotrexate; PB: peripheral blood;
PBSC: peripheral blood stem cell; RAST: radioallergosorbent test; RIC: reduced
intensity conditioning; RIST: radioimmunosorbent test; sjKRECs: signal joint
kappa-deleting recombination excision circles; STR: short tandem repeat;
TBI: total body irradiation; TLI: total lymphoid irradiation; TRECs: T-cell
receptor excision circles; XLA: X-linked agammaglobulinemia.
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